Your request to link to rcsb for Lysine-specific demethylase 5A


  • 2JXJ: nmr structure of the arid domain from the histone h3k4 demethylase rbp2 (10.1038/NSMB.1400 )
  • 2KGG: solution structure of jarid1a c-terminal phd finger (10.1038/NATURE08036 )
  • 2KGI: solution structure of jarid1a c-terminal phd finger in complex with h3(1-9)k4me3 (10.1038/NATURE08036 )
  • 2MNY: nmr structure of kdm5b phd1 finger (10.1007/S13238-014-0078-4 )
  • 2MNZ: nmr structure of kdm5b phd1 finger in complex with h3k4me0(1-10aa) (10.1007/S13238-014-0078-4 )
  • 3GL6: crystal structure of jarid1a-phd3 complexed with h3(1-9) k4me3 peptide (10.1038/NATURE08036 )
  • 5C11: crystal structure of jarid1a phd finger bound to histone h3c4me3 peptide
  • 5CEH: structure of histone lysine demethylase kdm5a in complex with selective inhibitor (10.1038/NCHEMBIO.2085 )
  • 5E6H: a linked jumonji domain of the kdm5a lysine demethylase (10.1074/JBC.M115.698449 )
  • 5ISL: linked kdm5a jmj domain bound to the inhibitor c49 (2-{[(2-{[(e)-2- (dimethylamino)ethenyl](ethyl)amino}-2-oxoethyl) amino]methyl}pyridine-4-carboxylic acid) (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVB: a high resolution structure of a linked kdm5a jmj domain with alpha- ketoglutarate (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVC: linked kdm5a jmj domain bound to the inhibitor n3 (4'-[(2- phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid) (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVE: linked kdm5a jmj domain bound to the inhibitor n8 ( 5-methyl-7-oxo-6- (propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile) (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVF: linked kdm5a jmj domain bound to the inhibitor n10 8-(1-methyl-1h- imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVJ: linked kdm5a jmj domain bound to the inhibitor n11 [3-({1-[2-(4,4- difluoropiperidin-1-yl)ethyl]-5-fluoro-1h-indazol-3-yl}amino) pyridine-4-carboxylic acid] (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVV: linked kdm5a jmj domain bound to the inhibitor n12 [3-((1-methyl-1h- pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid] (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IVY: linked kdm5a jmj domain bound to the inhibitor n16 [3-(2-(4- chlorophenyl)acetamido)isonicotinic acid] (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IW0: linked kdm5a jmj domain bound to the inhibitor n19 [2-(5-((4-chloro-2- methylbenzyl)oxy)-1h-pyrazol-1-yl)isonicotinic acid] (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5IWF: linked kdm5a jmj domain bound to the inhibitor 2-(((2-((2- (dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl) isonicotinamid (10.1016/J.CHEMBIOL.2016.06.006 )
  • 5K4L: crystal structure of kdm5a in complex with a naphthyridone inhibitor (10.1016/J.BMCL.2016.07.070 )
  • 5V9P: crystal structure of pyrrolidine amide inhibitor [(3s)-3-(4-bromo-1h- pyrazol-1-yl)pyrrolidin-1-yl][3-(propan-2-yl)-1h-pyrazol-5- yl]methanone (compound 35) in complex with kdm5a (10.1016/J.BMCL.2017.05.016 )
  • 5V9T: crystal structure of selective pyrrolidine amide kdm5a inhibitor n- {(3r)-1-[3-(propan-2-yl)-1h-pyrazole-5-carbonyl]pyrrolidin-3- yl}cyclopropanecarboxamide (compound 48) (10.1016/J.BMCL.2017.05.016 )
  • 6BGU: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl) (propoxy)methyl)-1h-pyrrolo[3,2-b]pyridine (compound n9) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BGV: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2- (piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7- carboxylic acid (compound n40) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BGW: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2- (4,4-difluoropiperidin-1-yl)ethoxy)methyl)-1h-pyrrolo[3,2-b]pyridine- 7-carboxylic acid(compound n41) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BGX: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)((4, 4-difluorocyclohexyl)methoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7- carboxylic acid(compound n42) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BGY: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2- (1-methylpyrrolidin-2-yl)ethoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7- carboxylic acid(compound 46) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BGZ: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2- (1-methyl-1h-imidazol-2-yl)ethoxy)methyl)-1h-pyrrolo[3,2-b]pyridine- 7-carboxylic acid (compound n47) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH0: linked kdm5a jmj domain bound to the inhibitor (r)-2-((2- chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2- b]pyridine-7-carboxylic acid (compound n51) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH1: linked kdm5a jmj domain bound to the inhibitor (s)-2-((2- chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2- b]pyridine-7-carboxylic acid (compound n52) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH2: linked kdm5a jmj domain bound to the inhibitor (r)-n-(1-(3-isopropyl- 1h-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (compound n54) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH3: linked kdm5a jmj domain bound to the inhibitor (s)-n-(1-(3-isopropyl- 1h-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (compound n55) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH4: linked kdm5a jmj domain bound to the inhibitor 5-(1-(tert-butyl)-1h- pyrazol-4-yl)-6-isopropyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine- 3-carbonitrile (compound n75/cpi-48) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6BH5: linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(3- (piperidin-1-yl)propoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7- carboxylic acid (compound n48) (10.1021/ACS.JMEDCHEM.8B00261 )
  • 6DQ4: linked kdm5a jmj domain bound to the inhibitor gsk-j1 (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQ5: linked kdm5a jmj domain bound to the inhibitor n43 i.e. 3-((6-(4- acryloyl-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino) propanoic acid (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQ6: linked kdm5a jmj domain bound to the inhibitor n44 i.e. 3-((2- (pyridin-2-yl)-6-(4-(vinylsulfonyl)-1,4-diazepan-1-yl)pyrimidin-4- yl)amino)propanoic acid (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQ7: linked kdm5a jmj domain bound to the potential hydrolysis product of inhibitor n45 i.e. 3-((6-(4-(2-cyano-3-methylbut-2-enoyl)-1,4- diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
  • 6DQ8: linked kdm5a jmj domain bound to the inhibitor n49 i.e. 2-((2- chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)thieno[3,2- b]pyridine-7-carboxylic acid (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQ9: linked kdm5a jmj domain bound to the covalent inhibitor n69 i.e. [2- ((3-acrylamidophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2- b]pyridine-7-carboxylic acid] (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQA: linked kdm5a jmj domain bound to inhibitor n70 i.e.[2-((3- aminophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7- carboxylic acid] (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQB: linked kdm5a jmj domain forming covalent bond to inhibitor n71 i.e. 2- ((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl) ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid (10.1021/ACS.JMEDCHEM.8B01219 )
  • 6DQC: linked kdm5a jmj domain bound to the inhibitor n50 i.e. 2-(4-((2- (dimethylamino)ethyl)(ethyl)carbamoyl)-5-(4-methoxyphenyl)-1h- pyrazol-1-yl)isonicotinic acid
  • 6DQD: linked kdm5a jmj domain bound to the inhibitor n53 i.e. 2-(5-([1,1'- biphenyl]-3-yl)-4-(1-(2-(piperidin-1-yl)ethoxy)ethyl)-1h-pyrazol-1- yl)isonicotinic acid
  • 6DQE: linked kdm5a jmj domain bound to the inhibitor n67 i.e. 2-(5-phenyl-4- (phenyl(2-(piperidin-1-yl)ethoxy)methyl)-1h-pyrazol-1-yl)isonicotinic acid
  • 6DQF: linked kdm5a jmj domain bound to the inhibitor n68 i.e. 2-(1-(2- (piperidin-1-yl)ethyl)-1h-benzo[d]imidazol-2-yl)thieno[3,2- b]pyridine-7-carboxylic acid
  • 7KLO: solution structure of the phd1 domain of histone demethylase kdm5a (10.1021/ACSCHEMBIO.0C00976 )
  • 7KLR: solution structure of the phd1 domain of histone demethylase kdm5a in complex with a histone h3(1-10) peptide (10.1021/ACSCHEMBIO.0C00976 )